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Background: Tiotropium is a new long-acting anticholinergic bronchodilator, which is
recommended as first-line therapy in the management of chronic obstructive pulmonary
disease (COPD). It is currently available in the form of a dry powder inhaler worldwide.
Some COPD patients find it difficult to generate inspiratory flow rates of up to 40 l/min,
which is required for the drug to reach the airways. To overcome this, a new pMDI form has
been developed for administration of tiotropium in patients with COPD. The clinical
efficacy of this mode of tiotropium delivery has, so far, not been compared with the
currently available dry powder inhaler (DPI) devices.
Aims and objectives: To compare the bronchodilator effects of a single dose of 18mcg of
tiotropium administered via a pressurized meter dose inhaler (pMDI) and spacer with the
currently available DPI form through Rotahalers.
Study design: A randomized, double-blind, double-dummy, three-period, placebo-
controlled, crossover, single-center study was conducted in 19 patients with stable COPD.
Single doses of tiotropium (18mcg) or placebo were administered on three separate study
days (4–7 days apart) through a Rotahalers and pMDI with a non-static spacer (Zerostat,
Cipla Ltd.). During each study visit forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) were measured over a period of 24 h at 11 different time points (0, 15,
30min, 1, 2, 3, 4, 6, 8, 12 and 24 h), using a bellows spirometer (Vitalographs 2160, UK)
while static parameters like inspiratory capacity (IC), residual volume (RV), intrathoracicElsevier Ltd. All rights reserved.
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Bronchodilator effect of pMDI tiotropium 2465gas volume (ITGV) and total lung capacity (TLC) were measured by bodyplethysmography
(Jaeger Masterscreen, Germany) at 0min, 3, 8 and 24 h.
Results: Tiotropium administered through both pMDI (and spacer) and DPI showed
significantly better mean FEV1 and mean FVC differences from baseline, in terms of mean
maximum change and area under curve over a period of 24 h (AUC0–24 h), as compared to
placebo. The mean IC and trough FEV1 values also improved significantly with tiotropium
administered through both the devices as compared to placebo. For all these parameters,
there was no difference in the efficacy between pMDI and DPI. There was also no significant
difference between the time to onset, time to maximum response and duration of
response between tiotropium administered through both the study devices. On the other
hand, there was no significant difference in RV, ITGV and TLC by a single dose of tiotopium
delivered through either of the devices when compared with placebo over a period of 24 h.
Conclusion: This is the first study to demonstrate that tiotropium administered by pMDI
and spacer shows a superior time-dependent bronchodilator response when compared to
placebo, and that this therapeutic efficacy is similar to tiotropium administered by DPI. We
recommend the use of tiotropium administered through a pMDI and spacer to those COPD
patients who prefer to use the pMDI device, and especially in those who cannot generate
sufficient inspiratory flows required for dry powder inhaler devices.
& 2007 Elsevier Ltd. All rights reserved.Background
The cholinergic nervous system plays an important role in the
pathophysiology of chronic obstructive pulmonary disease
(COPD). Anticholinergic drugs are effective not only in
relieving symptoms but also improve lung functions and
exercise tolerance.1 They are therefore recommended as the
bronchodilators of choice in COPD patients. Tiotropium is a
newly introduced inhaled long-acting muscranic subtype M1
and M3 receptor antagonist,2,3 which when administered
once daily produces marked beneficial effects on several
parameters such as forced vital capacity (FVC), forced
expiratory volume in 1 s (FEV1), inspiratory capacity (IC),
respiratory symptoms, exercise endurance and quality of
life.3–6,10,15,16,18,19 Currently, tiotropium is available for
inhalation only via dry powder inhaler (DPI) in many
countries. Although most COPD patients are comfortable
with this device, one of the drawbacks of using a DPI device is
that it requires generation of sufficient inspiratory flow rates
(at least 30–60 l/min) for adequate deposition of the drug
into the airways. Many COPD patients, particularly those who
have moderate-to-severe disease may find it difficult to
generate these inspiratory pressures and therefore find it
difficult to use the DPI device. In vitro deposition studies have
suggested that care should be taken when shifting from one
inhaler device to another because this may affect the actual
dose delivered to the lung and therefore comparison between
the efficacy of different inhaler devices is necessary to ensure
appropriate therapeutic effect.7–9 We have currently devel-
oped a tiotropium formulation to be administered via a pMDI.
The aim of this study was to compare the therapeutic efficacy
of tiotropium delivered by a pMDI and spacer versus that
administered by a DPI.
Materials and method
Subjects
Twenty-four stable moderate-to-severe COPD male and
females subjects aged 40–70 years were recruited into thisstudy. COPD was defined according to the Global Initiative of
Obstructive Lung Disease (GOLD) criteria viz. current or ex-
smokers with smoking history of at least 10 pack years or
significant occupational exposure symptoms of chronic
cough, sputum production, and breathlessness that is
progressive and persistent in nature, and a post-bronchodi-
lator FEV1/FVC ratio o0.7. Only subjects having an FEV1 of
o65% predicted and a bronchodilator reversibility of at
least 12% in FEV1, 30–45min after 40 mg of ipratopium
bromide were recruited in to the study. None of the subjects
had received oral corticosteroids or had history suggestive of
acute exacerbation for COPD for at least 4 weeks prior to
the start of the study. Pregnant and lactating women and
subjects with concomitant asthma, heart failure, cardiac
arrhythmia, ischemic heart disease and liver disease were
excluded from the study. Peripheral venous blood was
analyzed for routine hemogram and biochemistry during
the screening visit to rule out other associated disorders.
Chest X-ray was obtained to rule out any active pulmonary
disease or other concomitant diseases likely to affect the
study, e.g. lung carcinoma, bronchiectasis and pneumonia.
Intra-ocular pressure was measured in all subjects with a
tonometer (Schioetz tonometer, Bisro, Germany) to rule out
associated glaucoma, and those having raised intra-ocular
pressure were excluded from the study. The study was
approved by the independent local ethics committee and a
written informed consent was obtained from all study
subjects prior to the start of the study. The study was
conducted according to ICH-GCP guidelines.Study design
Single doses of 18mcg tiotropium [via pMDI plus spacer
(ZerostatTM spacer, Cipla Ltd., India) and DPI (Rotahalers,
Cipla Ltd.), India] and placebo were administered on three
separate days, at least 4 days apart, in this single-center
study, in a randomized, double-blind, double-dummy, cross-
over manner. Care was taken to ensure that the subjects had
avoided ipratopium for 12 h, short-acting b2 agonist for 6 h,
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agonist, long-acting oral xanthenes and oral leukotrienes for
at least 72 h prior to each study visit. During the study visits,
after determination of the baseline lung functions, the
subjects received study medication in a random order, using
a double-dummy technique. The medication was adminis-
tered between 7.30 and 9.00 a.m. during all study visits.
Subjects were asked to inhale tiotropium/placebo either
through the DPI or pMDI according to the standard methods
(one actuation of pMDI released 9mg of tiotropium, there-
fore two inhalations were required). The pMDI was primed
with two actuations before every inhalation. The subjects
were trained for the proper inhalation technique and the
study team monitored the study drug administration.
FEV1 and FVC were measured before and 15, 30min, 1, 2,
3, 4, 6, 8, 12 and 24 h after the study drug was administered
using bellows spirometer (Vitalographs 2160, UK), while IC
residual volume (RV), intrathoracic gas volume (ITGV) and
total lung capacity (TLC) were measured using a body-
plethysmograph (Jaeger Master Screen, Germany) before
and 3, 8 and 24 h (trough values) after administration of
study medications (Figure 1). Repeatability and acceptabil-
ity standards of lung functions were maintained according to
American Thoracic Society (ATS) criteria by a trained lung
function technician.
The primary efficacy variables used for analysis were
mean maximum difference in FEV1 and FVC from baseline
and FEV1 and FVC area under response curve over a period of
24 h. On the other hand, the secondary efficacy variables
were the mean maximum difference in the IC from the
baseline, mean maximum difference in the RV from the
baseline, mean difference in ITGV from the baseline, mean
difference in TLC from the baseline, time to onset of
bronchodilator response and time to maximum bronchodi-
lator response.Statistical analysis
Sample size estimation for this study was made using a PS
(Power and Sample size) software version 2.1.31 (Vander-
bilt, Canada). To achieve a power of 80% and show
equivalence at the significance level of 5% with a clinically
significant difference in FEV1 of 100ml and a standard
deviation in FEV1 of 150ml (based on our data of COPD
having moderate-to-severe COPD), a sample size of 18
subjects was estimated. We enrolled 24 subjects into the
study to cover for the dropouts.
Mean maximum change in FEV1 and FVC, the mean change
from the baseline in IC and the mean change from the
baseline in RV between the two formulations of tiotropium,
were analyzed using paired t-test. Area under curve (AUC)
was calculated for the absolute change in FEV1 and FVC from
the baseline over the 24 h study period using the trapezoidalTreatment A/B/C Screening
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Figure 1 Sturule. The AUC was measured for each patient on each
treatment regime. The AUCs between the two active
medication periods were compared using analysis of
variance (ANOVA). The confidence interval (CI) obtained
from this was used for the Schuirmann’s two–one-sided test
(TOST) of equivalence between the two active treatments.
An improvement of more than 100ml in FEV1 and 150ml in
FVC, IC, RV, ITGV and TLC were considered clinically
significant as efficacy endpoints.
Time to onset of response was defined as the first time
point after drug administration when a 100ml increase in
FEV1 and a 150ml increase in FVC were achieved. The time
point at which maximum response was observed during the
24 h study period was considered for time to maximum
response.Results
Of the 24 subjects screened, 20 were randomized
(4 subjects could not be randomized due to ischemic heart
disease or refusal to follow up), and 19 subjects completed
all the three study visits. One subject discontinued the study
due to noncompliance. Of the 19 subjects who completed
the study, 15 were chronic ex-smokers (mean smoking pack
years of 17.6 years), 2 (both females) had a history of
exposure to biomass fuel for 25–30 years and 2 had history of
occupational exposures (both were working in road con-
struction). The mean baseline FEV1 values were 0.7697
0.29 l. All of the subjects were on oral medications
(salbutamol and theopylline) before the enrollment; none
of them had used inhalation therapies before. The char-
acteristics of study subjects are summarized in Table 1.
Single doses of 18mcg tiotropium administered via pMDI
with spacer and 18mcg of tiotropium administered via DPI
produced a significantly better time-dependent bronchodi-
lator response as measured by AUC percentage change for
FEV1 and FVC from the baseline when compared to placebo
(p-values o0.01 for FEV1 and p-values o0.01 for FVC)
(Figures 2 and 3). The mean difference of AUC for percent
change in FEV1 and FVC between tiotropium delivered
through pMDI plus spacer and DPI from baseline to 24 h were
not significant [(FEV1 AUC024 h: 997 versus 1589 for pMDI
plus spacer and DPI, respectively; p40.05) (FVC AUC024 h:
526 versus 421 for pMDI and DPI, respectively; p40.05)]
(Figures 2 and 3 showing AUC FEV1 % change and FVC %
change, respectively), suggesting that 18mcg of tiotropium
delivered through pMDI plus spacer and 18mcg of tiotropium
delivered through DPI produced similar bronchodilator
responses when measured over 24 h.
The mean maximum change from the baseline for FEV1
was 384.2ml with pMDI plus spacer and 342.1ml with DPI
(Figure 4), while the mean maximum change from the
baseline for FVC was 564.2 and 573.2ml, respectivelyTreatment A/B/C Treatment A/B/C
s 
T
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WASHOUT
1 day 1 day
dy design.
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Bronchodilator effect of pMDI tiotropium 2467(Figure 5). These differences were not statistically signifi-
cant, suggesting that 18mcg of tiotropium delivered through
pMDI and 18mcg of tiotropium delivered through DPI
produced an equivalent mean maximum increase in FEV1
and FVC from the baseline values.
Tiotropium administered by pMDI plus spacer and DPI both
produced a significant increase in the IC at the 3rd and the
8th hour, post-administration, when compared with placebo
(pMDI plus spacer–placebo, 3rd hour p ¼ 0.01 and 8th hour
p ¼ 0.049; DPI–placebo, 3rd hour p ¼ 0.006 and 8th hour
p ¼ 0.03) (Figure 6). On the other hand, RV (Table 2), ITGV
and TLC did not show any significant reduction with0
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Figure 2 Mean percentage change in FEV1 over a period of 24 h fo
spacer, DPI and placebo.
Table 1 Demographic details of study subjects.
Variables Mean (SD)
Male/female 17/2
Mean age (years) 59.15 (7.98)
Smoking history (pack years) 17.61 (4.02)
Mean FEV1 (l) 0.77 (0.29)
Mean % predicted FEV1 33.80 (11.36)
Mean FEV1 reversibility
 (%) 25.52 (8.99)
Mean FVC (l) 1.60 (0.43)
Mean % predicted FVC 57.70 (15.07)
Mean FVC reversibility (%) 2.22 (13.23)
Mean IC (l) 1.28 (0.38)
Mean % predicted IC 52.50 (17.36)
Mean RV (l) 4.53 (2.02)
Mean % predicted RV 222.9 (110.78)
FEV1: forced expiratory volume after 1 s; FVC: forced vital
capacity; IC: Inspiratory capacity; RV: residual volume; S.D.:
standard deviation.
Change 30–45min after inhalation 40 mg of ipratopium
bromide.tiotropium administered via pMDI plus spacer and DPI versus
placebo, at any time point.
Tiotropium delivered by pMDI took 5.58 and 5.52 h to
reach maximum FEV1 and FVC response, while tiotropium
delivered through DPI took 6.42 and 5.34 h, respectively.
These difference were not statistically significant when
compared to each other (p ¼ 0.61). The time to onset of
bronchodilator response (increase of at least 100ml FEV1
from the baseline) for pMDI was 28.21min, while that of DPI
was 15.98min and the differences between the two were
not significant.Discussion
In this randomized, double-blind, double-dummy, placebo-
controlled crossover study, we have demonstrated for the
first time that a single dose of 18mcg tiotropium adminis-
tered via pMDI inhaler plus spacer produced a similar time-
dependent bronchodilator response as18mcg tiotropium
delivered through a DPI. Similarly, time to onset and time
to reach maximum FEV1 and FVC, were similar between the
two study devices. These results indicate that tiotropium
administered by a pMDI plus spacer produces an equivalent
bronchodilator therapeutic response as that administered by
a DPI.
Tiotropium is a new long-acting inhaled anticholinergic.
Clinical studies with single doses of inhaled tiotropium
confirm that it is a potent and long-lasting bronchodilator.
Furthermore, it protects against cholinergic bronchocon-
striction for more than 24 h and has been shown to improve
quality of life in patients with COPD; this has led it to be the
bronchodilator of choice in the management of COPD.
Tiotropium is usually available in a dry powder form all over
the world. Although in vivo data have not been conclusive,
most in vitro studies have implicated a need of high
inspiratory flow rates for the better drug delivery with the
dry powder inhaler devices.7,9 The pMDI with a spacer is an3
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Figure 3 Mean percentage change in FVC over a period of 24 h following a single-dose administration of tiotropium by pMDI plus
spacer, DPI and placebo.
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Figure 4 Change in mean maximum FEV1 from the baseline for
pMDI plus spacer, DPI and placebo.
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Figure 5 Change in mean maximum FVC from the baseline for
pMDI plus spacer, DPI and placebo.
B. Brashier et al.2468ideal alternative in subjects who are unable to generate an
adequate inspiratory flow rate. Moreover, pMDI offers a
combination of reliability, accurate dosing and low cost,
which makes it the more popular and a preferred form of
delivery in the treatment of COPD.
The pulmonary component of COPD is usually character-
ized by a progressive airflow limitation, which contributes to
respiratory symptoms and in order to reduce these symp-
toms, it is necessary to effectively reduce this air flow
limitation by dilating the airways. The spirometric para-
meters like FEV1, FVC values and FEV1/FVC ratio are the
best standardized, most reproducible and the most reliableobjective parameters available to measure airflow limita-
tion. These indices are the gold standard for diagnosing the
disease, staging the disease and for evaluating the response
to treatment. Our study demonstrated that 18mcg of
tiotropium administered via a pMDI formulation is as
effective as 18mcg dry powder tiotropium formulation,
when measured by percentage changes in FEV1 and FVC area
under curve from baseline to 24 h, trough FEV1 and FVC, and
mean maximum change in FEV1 and FVC. In addition, the
mean maximum improvement in FEV1 was 384.2ml with
pMDI plus spacer and 342.1ml with DPI, which was achieved
in 5.58 and 5.52 h, respectively. We believe this to be a
ARTICLE IN PRESS
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Table 2 Mean changes in RV (l) from baseline and 3, 8 and 24 h after tiotropium administration by pMDI+spacer and DPI and
placebo in n ¼ 19 subjects.
Medication 3 h (p-values) 8 h (p-values) 24 h (p-values)
Placebo 0.322 (0.3) 0.226 (0.56) 0.418 (0.4)
Tiotropium via DPI 0.188 (0.5) 0.386 (0.28) 0.394 (0.35)
Tiotropium via pMDI+spacer 0.321 (0.3) 0.798 (0.08) 0.398 (0.13)
Bronchodilator effect of pMDI tiotropium 2469clinically significant bronchodilator response in subjects
with moderate-to-severe COPD, who use either a DPI or a
pMDI with spacer further reinforcing the importance of
tiotropium in COPD subjects.
The amount of bronchodilator response seen in our
subjects with COPD after the administration of tiotropium
was higher than what we had anticipated and raises a
possible doubt of whether these subjects had concomitant
asthma. However, we feel confident that these subjects had
only underlying COPD based on their clinical presentation
and history. Calverley et al.11 and Donohue and co-workers12
earlier argued that nearly 50–70% COPD patients can show
significant bronchodilator reversibility with bronchodilators.
Our study adds to the growing body of evidence that COPD is
not necessarily an irreversible disease especially with the
advent of highly effective anticholinergic bronchodilator
drugs like tiotropium.
It has been suggested that severe COPD subjects may not
be able to generate adequate flow rates for attaining good
therapeutic response with DPI, we did not find any
difference in the bronchodilator response between the
tiotropium delivered through DPI and pMDI with the spacer
in different severities of COPDs. These observations were in
accordance with the observations made by Cuvelier et al.,13who had shown that ipratopium dry powdered form
produced an equivalent therapeutic response as pMDI
formulation in moderate-to-severe COPDs. Sarinas et al.14
have shown that the subjects with stable COPD of varying
severity could comfortably generate necessary flow rates to
operate new and currently available DPIs over wide range of
inspiratory flow rates.
Although, the degree of airflow limitation as measured
with spirometric indices like FEV1 still remains the defining
characteristic of COPD, it does not evaluate the full impact
of COPD in the patient’s life. This is because the pathology
of COPD is not only characterized by a progressive airflow
obstruction, but also a progressive destruction of supporting
tissues and elastin fibers of the lungs.15,16 As a result, during
exhalation the unsupported bronchioles collapse before the
full air is exhaled out, which leads to progressive air
trapping distally with increase in RV, ITGV, TLC and decrease
in the IC. The lung hyperinflation contributes to the
development of breathlessness and physical limitations.16–19
Hyperinflation increases the elastic load in the lungs and
diaphragm, which in turn increases the work of breathing,
disrupts the neuroventilatory coupling and finally leads to
increased perception of dyspnea.15,16 Amongst the static
lung volumes which a bodyplethysmograph can measure
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B. Brashier et al.2470(RV, IC, ITGV, TLC, etc.) IC has the highest correlation with
respiratory symptoms like dysponea in the COPD sub-
jects.15,16 Therefore, we measured resting IC at three
different time points post drug administration (3, 8 and
24 h) after tiotropium administration. An equivalent im-
provement in IC was noted particularly in the 3rd and 8th
hour, with mean maximum improvements of 350 and 379ml
after administration of tiotropium by pMDI plus spacer and
DPI. This was both statistically and clinically superior to that
of placebo suggesting that single doses of tiotropium reduce
lung hyperinflation markedly and that this effect starts
within 3 h of administration, and with a single dose lasts for
at least up to 8 h. The amount of improvement seen in IC in
our study is similar to that noted in an earlier study.15 An
improvement of over 350ml in IC in subjects with COPD
translates into significant improvements in clinical symp-
toms. An earlier study which administered tiotropium daily
for a period of 4 weeks, reported that the lung deflation
even persists after 24 h.15 It is likely that because ours was a
single-dose study, we did not observe significant improve-
ments in IC values at 24 h post-administration.
We had also measured RV, ITGV and TLC at baseline and at
three different time points as parameters to assess the
extent of lung deflation after tiotropium administration.
However, we did not find any significant reductions in RV,
ITGV and TLC after administration of single doses of
tiotropium through either of devices. Possible explanations
for these are: firstly, we had large standard deviation values
for RV, TLC and ITGV in our study subjects because we had
recruited subjects with varying severity of COPD. Probably,
this itself could possibly explain the lack of significant
effects on these values at different time points, following
administration of single dose of tiotropium. Secondly, our
COPD subjects had never received inhaled bronchodilators
before and were receiving only oral medications (salbutamol
and theophylline). Thirdly, it is likely that RV, TLC and ITGV
are less sensitive parameters than FEV1 and IC, and may
likely start showing significant improvements only after few
days of tiotropium administration particularly in the severe
COPD subjects. Santus et al.20 have earlier reported a
significant improvement in ITGV within 24 h following a
single dose of tiotropium administration. This is in contrast
to our observations, and clearly more studies are required to
evaluate the effects of single doses of tiotropium on RV, TLC
and ITGV in subjects with COPD.
In summary, a single dose of tiotropium administered via
pMDI formulation with a spacer produced an equivalent
time-dependent bronchodilator response, as measured by
changes in FEV1 and FVC, over 24 h as tiotropium adminis-
tered via a DPI formulation through a Rotahalers. In
addition, a single dose of tiotropium administered via both
the devices reduced lung hyperinflation (as measured by IC)
markedly, an effect which started within 3 h of administra-
tion. The amount of improvement in FEV1 and FVC noted in
our study with single doses of tiotropium administered via
both the devices adds to the body of evidence that COPD is
not necessarily a reversible airways disease. Thus, tiotro-
pium in pMDI formulation may be used routinely in patients
with COPD. Further studies involving larger number of
patients and for longer duration are required to determine
long-term safety, efficacy and effect on quality of life of
tiotropium administered via a pMDI.Conflict of interest
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